Correction to: Intervertebral disc penetration by antibiotics used prophylactically in spinal surgery: implications for the current standards and treatment of disc infections
Correction to: European Spine Journal (2019) 28:783–791 https://doi.org/10.1007/s00586-018-5838-z
The 3rd to last sentence of the Results section was incorrect in original publication. It should read as follows:
“The concentration of clindamycin in the NP was higher than those of cefazolin and vancomycin, and it was also a higher percentage of the antibiotic dose.”
Unfortunately, the complete conflict of interest statement was missed out in the original publication. The same is given below.
Conflict of interest MNC, OS, JES, FR, RJ, MS and CB have stock ownership or options in DiscitisDx, Inc. MNC and OS have filed several patent applications, which have been assigned to DiscitisDx, Inc.
JW has investments/options in Bone Biologics Inc., Expanding Orthopedics, Inc., Pearldriver, Inc., Electrocore, Inc., and SurgiTech, Inc. JW receives royalties from Biomet, Inc., Seaspine, Amedica Corp, and Synthes. JW is on the board of directors for North American Spine Society, AO Foundation, Cervical Spine Research Society, Society for Brain Mapping and Therapeutics, and the American Orthopaedic Association. JW is on the editorial boards of Spine, The Spine Journal, Clinical Spine Surgery, Global Spine Journal. JW has fellowship funding (paid to institution) from the AO Foundation.
SG holds stock in SI Bone, Inc, and Spinal Kinetics. SG is a consultant for Benvenue Medical, DePuy (Johnson & Johnson), EBI, Globus Intrinsic Therapeutics, Magnifi Group, Nuvasive, SI Bone, Inc., and Spinal Kinetics. SG receives institutional and/or research support from AO North America, DePuy (Johnson & Johnson), Globus Medical, Medtronic, Nuvasive, and Stryker.